Loading clinical trials...
Loading clinical trials...
YY-20394 Combined With GEMOX in the Treatment of Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma With a Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
Conditions
Interventions
YY-20394
Start Date
August 20, 2020
Primary Completion Date
October 1, 2021
Completion Date
December 1, 2021
Last Updated
August 5, 2020
NCT05006716
NCT06026319
NCT07368270
NCT07255963
NCT05940272
NCT06352242
Lead Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions